Toronto, Ontario–(Newsfile Corp. – July 6, 2022) – Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the “Company” or “TELO”) announces the completion of the laboratory processing and analysis component of its clinical trial for TELO’s leading prognostic test for smoldering multiple myeloma (“SMM”). The samples from SMM patients were provided by the Mayo Clinic in Q1 2022 as part of an ongoing collaboration to evaluate the company’s prognostic technology for multiple myeloma (“MM”). The TELO study results have now been sent back to the Mayo Clinic for review and comparative analysis.
In January 2020, TELO entered into a collaboration agreement with the Mayo Clinic to conduct clinical studies aimed at developing two clinical prognostic tests for MM, including TELO’s lead product to identify high-risk SMM patients. In May 2021, TELO completed a feasibility study with the Mayo Clinic, enabling TELO to advance the test to its current clinical trial phase, a critical step in the validation and commercialization of its SMM product.
The company’s TeloView® test for SMM has the potential to identify high-risk SMM patients who will benefit from prior treatment intervention; and equally important, the test has the potential to predict the larger subset of low-risk patients who have a more stable form of the disease and need no treatment. Low-risk SMM patients can be tested continuously for up to every three months to monitor their status without treatment intervention. TELO estimates, in consultation with industry leaders, that there are more than 200,000 patients in the US who could benefit from the TeloView® test for SMM, with a potential total addressable market of more than 500,000 tests per year.
To speed up the processing of the patient samples, TELO used its proprietary automation tools that were recently developed and validated, leveraging the power of artificial intelligence, machine learning and deep machine learning. The deployment of these automation tools in TELO’s workflow enabled TELO’s technical team to complete processing of the samples received from the Mayo Clinic approximately 25-30% ahead of schedule.
“We are very pleased to complete the processing of this large cohort of patient samples in record time, confirming the scalability and efficiency of TELO’s automated workflow,” said Sherif Louis, CEO of TELO. “We look forward to following up the results with the Mayo Clinic once their review process is complete.”
About smoldering multiple myeloma
SMM is a biological precursor to MM, a deadly cancer that forms in plasma cells, a type of white blood cell. SMM is generally asymptomatic, but approximately 15% of SMM patients transition to active MM each year, which is associated with marked pain, risk of bone fractures and other debilitating symptoms. MM has an average five-year survival rate of about 55%. Identifying high-risk SMM patients who will progress to active multiple myeloma remains a critical unmet need in the treatment of MM.
Telo Genomics Corp. is a biotech company pioneering the industry’s most comprehensive telomere platform with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing area of significant interest to the medical community because it is less invasive and easier to replicate than traditional diagnostic approaches. Combining our team’s significant expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-related genetic instability, TELO develops simple and accurate products that improve patient care by providing the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in more than 160 peer-reviewed publications and in more than 30 clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer’s disease. Our main application, TELO-MM, is being developed to provide medical professionals with important, actionable information in the treatment of multiple myeloma, a deadly form of blood cancer. For more information, visit www.telodx.com†
For more information, please contact:
MaRS Center, South Tower,
College Street 101, Suite 200,
Toronto, ON, M5G 1L7
Neither the TSX Venture Exchange nor its Regulation Services Provider (as this term is defined in the TSX Venture Exchange policies) assumes any responsibility for the suitability or accuracy of this release.
Warning Regarding Forward-Looking Statements
Certain information in this document may constitute “forward-looking information” under Canadian securities laws. In general, forward-looking information can be identified through the use of forward-looking terminology such as “intended”, “will”, or variations of such words and expressions or statements that certain actions, events or results “will” occur. Forward-Looking Statements Regarding Clinical Efficacy of Products, Commercial Viability of Products, Use of Revenue and Power of the TeloView platform for delivering personalized medicines that lead to better treatments and outcomes are based on company estimates and are subject to known and unknown risks, uncertainties and other factors that could cause actual results, activity level, performance or performance of the Company are materially different from those expressed or implied by such forward-looking statements or information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from the results anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or information incorporated herein by reference, except as required by applicable securities laws.
To view the source version of this press release, please visit: https://www.newsfilecorp.com/release/130081